en · de · es · fr · pt
melanotan-2-notes.peptides5388.com › Info › Chemistry And Receptor Pharmacology — Explained

Chemistry And Receptor Pharmacology — Explained

By Editorial Desk · published 2026-02-03 · last reviewed 2026-03-04 · Info

eumelanin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-03-04. Numbers and descriptions here follow the published literature rather than marketing material.

Chemistry and Receptor Pharmacology

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Chemical Background and Receptor Activity

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Cyclic heptapeptide, C-terminally amidated
Approximate molecular mass1024 DaMonoisotopic mass of the free peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
Solubility classSoluble in water and polar solventsAlso dissolves in neutral aqueous buffer
Common synonymsMelanotan II, MT-II, MT-2Described as a melanocortin agonist in early literature

Melanotan-2 Structure and Receptor Pharmacology

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Related pages on this site

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

Background and Mechanism of Melanotan-2

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Melanotan-2 Identity And Regulatory Status

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Supporting material

==== Photografting ==== The modification of inert surfaces of polyolefins, polyesters, and polyamides by grafting functional vinyl monomers has been used to increase hydrophobicity, dye absorption, and polymer adhesion. This photografting method is generally used during continuous filament or thin film processing. On a bulk commercial scale, the grafting technique is referred to as photoinitiated lamination, where desired surfaces are joined by grafting a polymeric adhesion network between the two films. The low adhesion and absorption of polyolefins, polyesters, and polyamides is improved by UV-irradiation of an initiator and monomer transferred through the vapor phase to the substrate. Functionalization of porous surfaces have seen great success with high temperature photografting techniques. In microfluidic chips, functionalizing channels allows directed flow to preserve lamellar behavior between and within junctions. The adverse turbulent flow in microfluidic applications can compound component failure modes due to the increased level of channel interdependency and network complexity. In addition, the imprinted design of microfluidic channels can be reproduced for photografting the corresponding channels with a high degree of accuracy.

Collagen alpha-2(IV) chain is a protein that in humans is encoded by the COL4A2 gene. This gene encodes one of the six subunits of type IV collagen, the major structural component of basement membranes. The C-terminal portion of the protein, known as canstatin, is an inhibitor of angiogenesis and tumor growth. Like the other members of the type IV collagen gene family, this gene is organized in a head-to-head conformation with another type IV collagen gene so that each gene pair shares a common promoter.

=== Synthesis === VWF is a large multimeric glycoprotein present in blood plasma and produced constitutively as ultra-large VWF in endothelium (in the Weibel–Palade bodies) and megakaryocytes (α-granules of platelets).

=== Biosynthesis === HMB is synthesized in the human body through the metabolism of L-leucine, a branched-chain amino acid. In healthy individuals, approximately 60% of dietary L-leucine is metabolized after several hours, with roughly 5% (2–10% range) of dietary L-leucine being converted to HMB.

==== Doggie Kruger ==== Anubian Doggie Kruger (アヌビス星人ドギー・クルーガー, Anubisu Seijin Dogī Kurūgā), also known as "Boss" (ボス, Bosu) to several of his subordinates, is from Planet Anubis and is the tough-yet-honorable superintendent of the Space Police's Metropolitan Police, as well as chief of its Earth branch. While operating as a Dekaranger in his younger years, he earned a legendary reputation as "Hell's Guard Dog" (地獄の番犬, Jigoku no Banken), due in part to his willingness to do anything to save those he cares about. Despite this, he displays feelings for his assistant Swan and panics whenever he hears she has an admirer. During the events of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Kruger investigated the alleged corruption of his superior Kight Reidlich, and was framed for murder and held captive for two years before his team rescues him in the present. Soon after, Kruger admits his feelings for Swan. In battle, Kruger is a practitioner of the Galaxy Sword-Style (銀河一刀流, Ginga Ittō-ryū) where he learned the style's secret technique, the Vega Impulse (ベガインパルス, Bega Inparusu). Though he is capable of destroying 100 foes without being defeated, he suffered from a spinal problem that caused him to miss once every 2000 attacks until being cured by chiropractor Yukito Sanjyo of the Abarangers. Additionally, utilizing a variant of the SP License called the Master License (マスターライセンス, Masutā Raisensu), Kruger can transform into the black-colored Deka Master (デカマスター, Deka Masutā).

Sources: en.wikipedia.org

Notes from published material

=== Oral GLP-1 Semaglutide Generic === SCD has been developing an oral generic version of semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic. In January 2026, SCD signed a partnership agreement with Daiichi Sankyo Espha, a subsidiary of Japan's Daiichi Sankyo, for the exclusive sale of oral semaglutide generics in Japan. Some industry observers and analysts have questioned the company's public statements regarding this product. A commentary published by the Korea Biomedical Review in July 2025 noted that SCD's claims of a potential 2026 market launch for its oral semaglutide generic appeared to overstate the company's regulatory position, given that secondary patents on semaglutide formulations are widely expected to remain in force until at least 2031 in most major markets.

== History == The chemical class of barbiturates are one of the oldest sedative-hypnotic agents known, dating back from the introduction of barbital in the early 20th century. In Hungary, hexobarbital (and other barbiturates) were regularly used as drugs by pregnant women attempting suicide. Hexobarbital was long thought to have potentially teratogenic and fetotoxic effects. The FDA has classified them as Pregnancy Category D or C. Some research however, indicate that ingestion of Hexobarbital might cause congenital abnormalities. During World War II, Herta Oberheuser was a Nazi physician and convicted war criminal, investigating the effects of hexobarbital. The experiments were mostly performed on woman prisoners in the Ravensbrück concentration camp.

==== Impeachment attempt ==== On 20 November 2021, Popular Force, Go on Country, and Popular Renewal backed a motion by Patricia Chirinos to impeach President Castillo for "moral incapacity." With the three parties only having 43 votes out of the 87 needed for impeachment, Popular Renewal parliamentarian José Cueto said that he was aware that the motion would fail, but hoped that the motion would get 52 signatures to allow for Congress to summon President Castillo for questioning before Congress. Free Peru's members initially presented contradictory statements on the impeachment. Meanwhile, Together for Peru denounced the impeachment attempt as a "coup maneuver." On 28 November 2021, Cuarto Poder teased footage of various people entering Castillo's campaign house in Breña. Among these people were Castillo, who entered without his characteristic Chotano hat. As the meetings were unregistered (against Peruvian regulations), many hyped up the Cuarto Poder reports as a prelude to a major corruption expose against Castillo's administration. On 6 December 2021, Free Peru concluded an extraordinary national assembly by announcing that it would vote unanimously against an impeachment. On 1 December 2021, Prime Minister Mirtha Vásquez assured that the Breña house and other places outside the Government Palace will no longer be used for meetings and assured that measures would be taken in order to improve transparency. Vásquez also said Castillo would be willing to be transparent regarding the people he met at the Breña house.

High mass accuracy: The mass deviation of the input spectra should be within 20 ppm. Mass spectrometry devices such as TOF, Orbitrap and FT-ICR usually provide data with high mass accuracy, as do coupled devices such as Q-TOF, IT-TOF or IT-Orbitrap. Spectra measured with a quadrupole or linear trap do not provide the required accuracy for data analysis with SIRIUS. Rich fragmentation spectra: It is not possible to deduce the structure or even the molecular formula from an MS2 spectrum that contains almost no peaks. Prior noise filtering of the spectra is not necessary and not favorable. SIRIUS considers up to 60 peaks in the fragmentation spectrum and decides for itself which of these peaks are regarded as noise. Centroided MS data: SIRIUS does not contain routines for peak picking from profile-mode spectra. msConvert in ProteoWizard can be used to convert to centroided data. Additionally, there are several tools specialized for the preprocessing task, such as OpenMS, MZmine or XCMS. OpenMS and MZmine 3 both provide export functions tailored to the needs for SIRIUS. Different common MS file formats, such as .csv, .ms or .mgf files, can be imported to SIRIUS. SIRIUS can import full LC-MS-runs (.mzML) or single compounds. At present, SIRIUS only handles single-charged compounds.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II identical to alpha-melanocyte-stimulating hormone?

No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.

How does melanotan II differ from afamelanotide?

Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.

Is the receptor binding profile well established?

Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.

What class of compound is melanotan-2?

It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.

Network